Navidea Biopharmaceuticals Inc.
NAVB
NAVB was delisted on the 5th of October, 2023.
35 hedge funds and large institutions have $3.77M invested in Navidea Biopharmaceuticals Inc. in 2021 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 4 reducing their positions, and 3 closing their positions.
225% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 4
11% more capital invested
Capital invested by funds: $3.4M → $3.77M (+$376K)
5% less call options, than puts
Call options by funds: $369K | Put options by funds: $390K
3% less funds holding
Funds holding: 36 → 35 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$216K |
| 2 |
Renaissance Technologies
New York
|
+$178K |
| 3 |
Two Sigma Advisers
New York
|
+$117K |
| 4 |
Two Sigma Investments
New York
|
+$99.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$87.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$71K |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$48.2K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
-$27.5K |
| 4 |
Wolverine Trading
Chicago,
Illinois
|
-$9.66K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.51K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
26
Tower Research Capital (TRC)
New York
| $2K | +$1.83K | +783 | New |
|
|
SIS
27
Sound Income Strategies
Ft Lauderdale,
Florida
| $1.21K | – | – | – |
|
|
PA
28
Parallel Advisors
San Francisco,
California
| $1K | – | – | – |
|
|
KFS
29
Kelly Financial Services
Braintree,
Massachusetts
| $101 | – | – | – |
|
|
SFI
30
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
| – | -$71K | -32,822 | Closed |
|
|
31
Simplex Trading
Chicago,
Illinois
| – | -$27.5K | -11,755 | Closed |
|
|
ASN
32
Advisory Services Network
Atlanta,
Georgia
| – | -$1K | -250 | Closed |
|
33
Osaic Holdings
Scottsdale,
Arizona
| – | +$337 | +144 | +2,400% |
|
NAVB Hedge Fund Activity: Q1 2021 in Review
35 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Navidea Biopharmaceuticals Inc. (NAVB) for Q1 2021, worth a combined $3.77M — up 11% from $3.4M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of NAVB and 2 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 13 added.
The largest buyer was Bridgeway Capital Management, adding an estimated $216K. The largest seller was Susquehanna Fundamental Investments, exiting entirely with an estimated $71K sold.
- 35 institutional investors held Navidea Biopharmaceuticals Inc. (NAVB) as of Q1 2021, down from 36 in Q4 2020.
- Funds reported $3.77M of Navidea Biopharmaceuticals Inc. stock for Q1 2021, up 11% quarter-over-quarter.
- 2 funds opened new Navidea Biopharmaceuticals Inc. positions in Q1 2021 and 3 closed out, a net change of -1 holder.
- The largest Navidea Biopharmaceuticals Inc. buyer in Q1 2021 was Bridgeway Capital Management, an estimated $216K added.
- The largest Navidea Biopharmaceuticals Inc. seller in Q1 2021 was Susquehanna Fundamental Investments, an estimated $71K sold.
Based on aggregated 13F filings for Q1 2021.